EVENTS & PRESENTATIONS
Translational and Clinicall Development of Clostridium novyi-NT
May 8-9, 2018Activity of the ERK1/2 inhibitor Ulixertinib in patients with BRAF and NRAS mutant melanoma
October 18 – 21, 2017Clostridium novyi-NT: Translational and Clinical Development
July 11 - 12, 2017First-in-class oral ERK1/2 inhibitor Ulixertinib (BVD-523) in patients with advanced solid tumors: Final results of a phase I dose escalation and expansion study
June 3, 2017Activity of the ERK1/2 inhibitor ulixertinib (BVD-523) in patients with BRAF and NRAS mutant melanoma
April 2, 2017Phase I clinical study of intratumoral injection of Clostridium novyi-NT spores in patients with advanced cancer
November 29 - December 2, 2016Dose escalation stage of a first-in-class phase I study of the novel oral ERK 1/2 kinase inhibitor BVD-523 (ulixertinib) in patients with advanced solid tumors
May 29 - June 2, 2015The selective ERK inhibitor BVD-523 is active in models of MAPK pathway-dependent cancers, including those with intrinsic and acquired drug resistance
April 18 - 22, 2015Phase I clinical study of intratumoral injection of Clostridium novyi-NT spores in patients with advanced cancer
March 2 - 4, 2015Phase 1 Trial of Image-Guided Oncolysis by Clostridium Novyi-NT Spore Inoculation: Early Technical Insights
January 31, 2015PUBLICATIONS
White paper on microbial anti-cancer therapy and prevention
Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine
Tumor stroma-targeted antibody-drug conjugate triggers localized anticancer drug release
Immune response to C. novyi-NT immunotherapy
Identification of immunologic and clinical characteristics that predict inflammatory response to C. Novyi-NT bacteriolytic immunotherapy
Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)
Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature.
[(124)I]FIAU: Human dosimetry and infection imaging in patients with suspected prothetic joint infection.
MRI-Monitored intra-tumoral injection of iron-oxide labeled Clostridium novyi-NT anaerobes in pancreatic carcinoma mouse model.
Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses.
Systematic repurposing screening in xenograft models identifies approved drugs with novel anti-cancer activity.
Evaluation of 1-(2-deoxy-2-fluoro-1-D-arabinofuranosyl)-5-iodouracil (FIAU) as an ex vivo bacterial detection agent.
TNF-Alpha blockade is ineffective in animal models of established polycystic kidney disease.
Possible therapeutic effect of trilostaine in rodent models of inflammation and nociception.
Novel anti-inflammatory effects of doxazosin in rodent models of inflammation.
Differential effects of cyclosporin and etanercept treatment on various pathologic parameters in a murine model of irradiation-induced mucositis.
Effect of the antipsychotic agent amisulpride on glucose lowering and insulin secretion.
Novel anti-inflammatory effects of repaglinide in rodent models of inflammation.
In vivo effects of immunomodulators in a murine model of Fluorouracil-induced mucositis.
Anti-inflammatory and immunomodulatory effects of bortezomib in various in vivo models.
PRESS RELEASES
Bacterial Therapy Tolerable, Shows Early Promise in Patients With Advanced Solid Tumors
September 30, 2018First-in-class ERK1/2 inhibitor safe, shows early efficacy in patients with advanced solid tumors
December 15, 2017First-in-class ERK inhibitor ulixertinib (BVD-523) shows promise in preclinical cancer models
October 3, 2017BioMed Valley Discoveries announces presentation of early clinical activity of first-in-class cancer therapy ulixertinib at 2017 ASCO annual meeting
May 26, 2017Bacterial biosurgery shows promise for reducing the size of inoperable tumors
August 13, 2014MEDIA
The media relations team at the BioMed Valley Discoveries works with local, regional, national, and international media organizations to provide reporters with accurate and timely information about our latest discoveries.
Members of the news media may email inquiries to mediacontact@biomed-valley.com or contact Kimberly Bland, PhD, at 816-389-8848.
If you are not a member of the news media or do not have a media-related question, please use the contact form.